India, Oct. 27 -- Nautilus Biotechnology, Inc. (NAUT) reported third quarter 2026 financial results and announced progress in its proteomics platform development, including participation in a four-year research consortium funded by the Advanced Research Projects Agency for Health (ARPA-H).
Third Quarter 2026 Financial ResultsRevenue for the third quarter of 2026 was $0.2 million, primarily from grant revenue related to The Michael J. Fox Foundation and services provided through the Iterative Mapping Early Access Program. The company reported no revenue in the third quarter of 2025.
Operating expenses increased 10% to $16.9 million from $15.5 million in the same period last year, mainly due to higher laboratory and professional services co...